ClinicalTrials.gg
TerminatedNCT05745844HORMESUpdated Oct 2, 2026

Evaluation of Neuromuscular ElectroStimulation in Addition to a Physical Activity Program

An interventional study of activity sessions in Prostate Cancer, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Terminated at 1 site in France. Open to male participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Recruitment has slowed considerably in recent months, making it particularly difficult to enroll new participants. This slowdown is partly due to recent changes in the management of prostate cancer.
Updated Oct 2, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 509 studies in Prostatic Neoplasms with a site in France — 89 open to participants now, 154 under way, 50 of them phase 3. Prostatic Neoplasms · France.

Enrollment
362nd of 405
28 · median 185
Started
2023
with 28 others
No phase
121 of 509
25 open now
Registered
406th of 509
by date

Among the 509 studies in Prostatic Neoplasms with a site in France, this one is the 362nd largest by enrollment of the 405 interventional ones that give a count, is one of 29 that started in 2023, is one of 121 with no phase, and was the 406th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

89 of the 509 studies in Prostatic Neoplasms with a site in France are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 90 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 509 studies in Prostatic Neoplasms with a site in France, or all of them as a file.
02

Study summary

The purpose of the study is to measure the muscle strength of the quadriceps 6 months from the start of the intervention, either the maximum load resistance that can be lifted in a single repetition under standardized conditions with the thigh press.

Read the detailed description

This is a prospective, longitudinal, open, comparative (two arms), randomized, monocentric study, focusing on a therapeutic strategy (muscle strengthening program with or without NeuroMuscular ElectroStimulation).

Patients will be cared for according to a nutritional and sports support program offered routinely in the investigating center, which corresponds to the recommendations for the care of patients with prostate cancer under Androgen Deprivation Therapy.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient treated with pharmacological androgen deprivation therapy for prostate cancer for more than 26 weeks;
  • Performance index (WHO): 0 or 1;
  • Patient able to understand the information related to the study, to read the information leaflet and having consented to participate in the study;
  • Patient benefiting from a social security scheme;

Exclusion criteria

Exclusion Criteria:

  • Weight ≥ 130 kg;
  • Vegetarian food;
  • Other associated neoplasia;
  • Patient having undergone a bilateral orchiectomy;
  • Painful bone , or at risk of fracture;
  • Anemia ( \< 10 g/dL);
  • Thrombocytopenia ( \< 50 G/L);
  • Renal impairment ( \< 60 mL/min, or albuminuria > 30);
  • Patient planning to travel more than 4 weeks continuously in the next 52 weeks;
  • Absolute to physical training (e.g. musculoskeletal, cardiovascular or neurological disorders), according to the doctor specializing in the associated medical condition;
  • Contraindication to the use of the neuromuscular electrostimulation device or the impedance meter, in particular infectious disease in the acute phase, fungal infection, dermatitis, unbalanced arrhythmia, epilepsy, wearing an active implantable device (pacemaker, heart artificial, prosthesis incorporating an electromagnetic system), open wound;
  • Sports activity already supervised by a third party or at an equal or higher level than the bodybuilding/muscle strengthening work recommended in the study;
  • Protected adult patient (under guardianship or curatorship, or under a regime of deprivation of liberty);
  • Patient participating in another research, or in a period of exclusion from another research.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    NeuroMuscular Electro Stimulation group

    Patients in the NeuroMuscular Electro Stimulation group will also have neurostimulation sessions using a CE marked medical device, in its destination, according to its instructions for use, therefore without expected clinical risk

    Other: activity sessions

  • Active comparator
    Control Group

    The control group (without NeuroMuscular Electro Stimulation) corresponds to the standard care routinely offered to patients in the investigating centre.

    Other: activity sessions

Interventions

  • Otheractivity sessions

    77 activity sessions ; muscle strengthening, testing or unloading

06

What researchers measure

Primary outcomes

  1. Quadriceps muscle strength

    Muscular strength of the quadriceps at 6 months from the start of the intervention, i.e. the maximum resistance / load that can be lifted in a single repetition, under standardized conditions. The main analysis is the comparison of quadriceps muscle strength (Maximum Resistance raised in 1 repetition) at 6 months between the groups with neuromuscular electrical stimulation and without neuromuscular electrical stimulation.

    Time frame: 6 months

07

Study locations

1 site
  • Hôpital privé Pays de Savoie
    Annemasse, 74100, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2023 to primary completion in Aug 2026, 31 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jun 2027 → Aug 2026 and completion Jun 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 27, 2023
StartActual
Dec 20, 2023
Primary completionActual
Aug 4, 2026was Jun 2027
CompletionActual
Aug 4, 2026was Jun 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Recruitment has slowed considerably in recent months, making it particularly difficult to enroll new participants. This slowdown is partly due to recent changes in the management of prostate cancer.
changed Oct 2, 2026
Primary completion
Jun 2027→Aug 4, 2026 (actual)
Oct 2, 2026
Study completion
Jun 2027→Aug 4, 2026 (actual)
Oct 2, 2026
Enrollment
48 (estimated)→28 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Terminated
    Why stopped Recruitment has slowed considerably in recent months, making it particularly difficult to enroll new participants. This slowdown is partly due to recent changes in the management of prostate cancer.
    Primary completion Jun 2027→Aug 4, 2026 (now actual)
    Study completion Jun 2027→Aug 4, 2026 (now actual)
    Enrollment 48 (estimated)→28 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05745844
Collaborators
Euraxi Pharma
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Dec 20, 2023
Primary completion
Aug 4, 2026
Completion
Aug 4, 2026
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion